Loading company
Hemab Therapeutics Holdings, Inc.
COAG · Nasdaq · Healthcare · Biotechnology
Next earnings: November 10, 2026
$34.74-2.7%Sep 25 close
- 1M
- -22.5%
Built from Hemab Therapeutics Holdings, Inc.’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
COAG · Nasdaq · Healthcare · Biotechnology
Next earnings: November 10, 2026
$34.74-2.7%Sep 25 close
Is the business getting bigger, and does it generate real cash?
Only 0 of the 5 checks below could be answered from this company’s filings, which is too few to put it on the scale. This company has not filed an annual report yet, so there is no completed financial year to measure it against. Every check here compares the latest figures with a year the company has closed and reported — recent listings and newly registered filers land here until their first annual report. Whatever did resolve is still shown — it is just not enough for a letter.
There is no grade history to chart for Hemab Therapeutics Holdings, Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.